Document Detail

Strength training does not alter the effects of testosterone propionate injections on high-density lipoprotein cholesterol concentrations.
MedLine Citation:
PMID:  10599978     Owner:  NLM     Status:  MEDLINE    
The purpose of the study was to examine the long-term effects of a high-volume strength training program (vertical ladder climbing) and testosterone propionate injections (intraperitoneal) on serum lipid and lipoprotein concentrations in male Sprague-Dawley rats. The animals were randomly divided into a testosterone (T)-treated group (dose per injection, 2.5 mg/kg testosterone propionate solubilized in 1 mL safflower oil) and a control (C) group (injected with an isovolumic amount of safflower oil alone). Animals were further divided into a strength-trained group (E) and a sedentary group (S). The 10-week resistance training program consisted of weights (100% of body mass) appended to the tail as the animal climbed an 85-cm ladder to volitional fatigue. Following 10 weeks of strength training and testosterone injections, body weight was not significantly different between the main effects of strength training exercise (TE + CE v TS + CS) and testosterone injections (TE + TS v CE + CS) or between groups. Testicular mass (mean +/- SE) was measured as a relative indicator of testosterone effects. Both TE and TS had significantly reduced testicular mass (2.56 +/- 0.04 and 2.38 +/- 0.03 g, respectively) compared with CE and CS (3.49 +/- 0.03 and 3.49 +/- 0.04 g, respectively). No significant differences were observed between groups for total serum cholesterol, serum triglycerides, or serum low-density lipoprotein cholesterol (LDL-C). In contrast, significant decreases in high-density lipoprotein cholesterol (HDL-C) were observed for both TE (26.7 +/- 1.6 mg/dL) and TS (27.5 +/- 1.3 mg/dL) compared with CE (48.7 +/- 2.9 mg/dL) and CS (43.5 +/- 2.6 mg/dL). As a result, the total cholesterol to HDL-C ratio was significantly greater for TS + TE (4.7 +/- 0.1) compared with CS + CE (2.9 +/- 0.2). These observations suggest that in animals, a 10-week program of high-volume strength training does not elicit any beneficial effect on the lipid or lipoprotein status, nor does it attenuate the altered lipoprotein profile induced by testosterone propionate injections.
F Frisch; K D Sumida
Related Documents :
15240618 - Lipid profile disorders induced by long-term cessation of physical activity in previous...
2058588 - Effects of a very-low-calorie diet and physical-training regimens on body composition a...
21058748 - Dietary supplements and team-sport performance.
23274098 - Preoperative diet impacts the adipose tissue response to surgical trauma.
25049488 - Pork preference for consumers in china, japan and south korea.
23448018 - Biological control of eotetranychus lewisi and tetranychus urticae (acari: tetranychida...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  48     ISSN:  0026-0495     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  1999 Dec 
Date Detail:
Created Date:  1999-12-29     Completed Date:  1999-12-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1493-7     Citation Subset:  IM    
Department of Biological Sciences, Chapman University , Orange, CA 92866, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cholesterol / blood
Cholesterol, HDL / blood*
Cholesterol, LDL / blood
Osmolar Concentration
Physical Conditioning, Animal / physiology*
Rats, Sprague-Dawley
Testosterone / pharmacology*
Triglycerides / blood
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Triglycerides; 57-88-5/Cholesterol; 58-22-0/Testosterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tumor necrosis factor alpha signaling pathway and apoptosis in pancreatic beta cells.
Next Document:  The narrow therapeutic window of glycated hemoglobin and assay variability.